cabozantinib, new first line treatment for kidney cancer
Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or... Read More
Cabozantinib Effective in Real-World Analysis for Relapsed Mrcc
Cabozantinib is a safe and effective treatment option for patients with relapsed renal cell carcinoma (RCC) in every clinical practice, according to... Read More
CABOSUN trail shines for Cabozantinib
New CABOSUN Data Show Better PFS With Cabozantinib in mRCC Read the full article HERE Updated results from the phase II CABOSUN... Read More
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared... Read More
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup... Read More
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the drug cabozantinib (Cabometyx) be made... Read More
SMC approve of nivolumab and cabozantinib
Statement from Kidney Cancer Scotland on the news of the SMC’s approval of nivolumab and cabozantinib for late stage kidney cancer patients... Read More
Hopes for Cabozantinib NICE recommendation
Kidney Cancer UK is very disappointed to hear that at the midpoint of the Single Technology Appraisal (STA) of cabozantinib, NICE is... Read More
Cabozantinib unlikely to be recommended based on cost: NICE and Ipsen in talks
NICE and Ipsen are continuing to discuss whether cabozantinib (Cabometyx) is to be recommended for use on the NHS in England and Wales. Cabozantinib,... Read More
New drug cabozantinib for treating advanced kidney cancer under NICE review.
New drug cabozantinib, for use in treating advanced kidney cancer (approved by the FDA in the USA), is currently in the process of... Read More
Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC
OncLive reports that a trial in the USA of novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx)... Read More
Kidney Cancer UK represents patients at NICE appraisals
On the 10th May 2018 the National Institute for Care and Health Excellence (NICE) appraised two different drug treatments in two meetings. The... Read More
Hollyann Prince – kidney cancer you truly suck
Added 2nd July 2018: We were deeply saddened to hear that Hollyann passed away on the 25th June, our thoughts and condolences... Read More
The Evolving Management of Advanced Renal Cell Carcinoma
A review from the American website Urototady.com of Dr. Rana R. McKay State-of-the-Art lecture providing a comprehensive presentation of the evolving management... Read More
Recent developments and future clinical trials for advanced kidney cancer:
immunotherapy and drug combinations including cabozantinib and nivolumab. *You may find our Glossary of Terms useful when reading this article Good news:... Read More
Three different appraisals in the pipeline for 2017 from NICE
Earlier this year, Kidney Cancer UK sent comments to the National Institute for Health and Care Excellence (NICE) for three different appraisals. ... Read More
Dave Chessum – My Kidney Cancer Journey
Dave shared his journey which has included being treated with and the side effects of the drugs axitinib, everolimus and the new drug cabozantinib.
EMA recommends two new kidney cancer drugs
Two new drugs for the treatment of adults with advanced kidney cancer are being recommended by the European Medicines Agency (EMA) for... Read More
Drug Treatments for Kidney Cancer
Your drug treatments for kidney cancer will be based on the stage and grade of your cancer and your general health. Staging... Read More